Niagara Dialysis Center is a medicare approved dialysis facility center in Niagara Falls, New York and it has 13 dialysis stations. It is located in Niagara county at 2932 Military Road, Niagara Falls, NY, 14304. You can reach out to the office of Niagara Dialysis Center at (716) 297-4059. This dialysis clinic is managed and/or owned by Davita. Niagara Dialysis Center has the following ownership type - Profit. It was first certified by medicare in January, 2015. The medicare id for this facility is 332720 and it accepts patients under medicare ESRD program.
| Name | Niagara Dialysis Center |
|---|---|
| Location | 2932 Military Road, Niagara Falls, New York |
| No. of Dialysis Stations | 13 |
| Medicare ID | 332720 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 2932 Military Road, Niagara Falls, New York, 14304 | |
| (716) 297-4059 | |
News Archive
By solving a long standing scientific mystery, the common saying "you just hit a nerve" might need to be updated to "you just hit a Merkel cell," jokes Jianguo Gu, PhD, a pain researcher at the University of Cincinnati.
Noting that the "roll-out of antiretroviral treatment for HIV in sub-Saharan Africa has been accompanied by rising rates of drug resistance," Raph Hamers, a global health research fellow at the Academic Medical Centre of the University of Amsterdam, and colleagues "call for improved patient management and the integration of population-based drug resistance surveillance into national treatment programs" in this BMJ analysis.
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the lab of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole is Highly Synergistic with HCV Protease Inhibitors".
› Verified 9 days ago
| NPI Number | 1619377330 |
| Organization Name | Niagara Dialysis Center |
| Doing Business As | Liberty Rc Inc |
| Address | 2932 Military Rd Niagara Falls, New York, 14304 |
| Phone Number | (716) 297-4059 |
News Archive
By solving a long standing scientific mystery, the common saying "you just hit a nerve" might need to be updated to "you just hit a Merkel cell," jokes Jianguo Gu, PhD, a pain researcher at the University of Cincinnati.
Noting that the "roll-out of antiretroviral treatment for HIV in sub-Saharan Africa has been accompanied by rising rates of drug resistance," Raph Hamers, a global health research fellow at the Academic Medical Centre of the University of Amsterdam, and colleagues "call for improved patient management and the integration of population-based drug resistance surveillance into national treatment programs" in this BMJ analysis.
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the lab of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole is Highly Synergistic with HCV Protease Inhibitors".
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 18 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 22 |
News Archive
By solving a long standing scientific mystery, the common saying "you just hit a nerve" might need to be updated to "you just hit a Merkel cell," jokes Jianguo Gu, PhD, a pain researcher at the University of Cincinnati.
Noting that the "roll-out of antiretroviral treatment for HIV in sub-Saharan Africa has been accompanied by rising rates of drug resistance," Raph Hamers, a global health research fellow at the Academic Medical Centre of the University of Amsterdam, and colleagues "call for improved patient management and the integration of population-based drug resistance surveillance into national treatment programs" in this BMJ analysis.
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the lab of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole is Highly Synergistic with HCV Protease Inhibitors".
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 62 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 426 |
| Percentage of adult patients getting regular hemodialysis at the center | 97 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
By solving a long standing scientific mystery, the common saying "you just hit a nerve" might need to be updated to "you just hit a Merkel cell," jokes Jianguo Gu, PhD, a pain researcher at the University of Cincinnati.
Noting that the "roll-out of antiretroviral treatment for HIV in sub-Saharan Africa has been accompanied by rising rates of drug resistance," Raph Hamers, a global health research fellow at the Academic Medical Centre of the University of Amsterdam, and colleagues "call for improved patient management and the integration of population-based drug resistance surveillance into national treatment programs" in this BMJ analysis.
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the lab of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole is Highly Synergistic with HCV Protease Inhibitors".
› Verified 9 days ago
| Adult patients getting regular peritoneal dialysis at the center | 5 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 49 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
By solving a long standing scientific mystery, the common saying "you just hit a nerve" might need to be updated to "you just hit a Merkel cell," jokes Jianguo Gu, PhD, a pain researcher at the University of Cincinnati.
Noting that the "roll-out of antiretroviral treatment for HIV in sub-Saharan Africa has been accompanied by rising rates of drug resistance," Raph Hamers, a global health research fellow at the Academic Medical Centre of the University of Amsterdam, and colleagues "call for improved patient management and the integration of population-based drug resistance surveillance into national treatment programs" in this BMJ analysis.
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the lab of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole is Highly Synergistic with HCV Protease Inhibitors".
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Niagara Dialysis Center with elevated calcium levels.
| Patients with hypercalcemia | 67 |
| Hypercalcemia patient months | 488 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 72 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 28 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 25 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 20 |
| Patients with Serumphosphor greater than 7 mg/dL | 17 |
News Archive
By solving a long standing scientific mystery, the common saying "you just hit a nerve" might need to be updated to "you just hit a Merkel cell," jokes Jianguo Gu, PhD, a pain researcher at the University of Cincinnati.
Noting that the "roll-out of antiretroviral treatment for HIV in sub-Saharan Africa has been accompanied by rising rates of drug resistance," Raph Hamers, a global health research fellow at the Academic Medical Centre of the University of Amsterdam, and colleagues "call for improved patient management and the integration of population-based drug resistance surveillance into national treatment programs" in this BMJ analysis.
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the lab of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole is Highly Synergistic with HCV Protease Inhibitors".
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 43 |
| Patient months included in arterial venous fistula and catheter summaries | 254 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 59 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 26 |
News Archive
By solving a long standing scientific mystery, the common saying "you just hit a nerve" might need to be updated to "you just hit a Merkel cell," jokes Jianguo Gu, PhD, a pain researcher at the University of Cincinnati.
Noting that the "roll-out of antiretroviral treatment for HIV in sub-Saharan Africa has been accompanied by rising rates of drug resistance," Raph Hamers, a global health research fellow at the Academic Medical Centre of the University of Amsterdam, and colleagues "call for improved patient management and the integration of population-based drug resistance surveillance into national treatment programs" in this BMJ analysis.
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the lab of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole is Highly Synergistic with HCV Protease Inhibitors".
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 48 |
| Hospitalization Rate in facility | 197.1 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 364.7 |
| Hospitalization Rate: Lower Confidence Limit | 111.8 |
News Archive
By solving a long standing scientific mystery, the common saying "you just hit a nerve" might need to be updated to "you just hit a Merkel cell," jokes Jianguo Gu, PhD, a pain researcher at the University of Cincinnati.
Noting that the "roll-out of antiretroviral treatment for HIV in sub-Saharan Africa has been accompanied by rising rates of drug resistance," Raph Hamers, a global health research fellow at the Academic Medical Centre of the University of Amsterdam, and colleagues "call for improved patient management and the integration of population-based drug resistance surveillance into national treatment programs" in this BMJ analysis.
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the lab of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole is Highly Synergistic with HCV Protease Inhibitors".
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at Niagara Dialysis Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 32.2 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 47.3 |
| Readmission Rate: Lower Confidence Limit | 19.8 |
News Archive
By solving a long standing scientific mystery, the common saying "you just hit a nerve" might need to be updated to "you just hit a Merkel cell," jokes Jianguo Gu, PhD, a pain researcher at the University of Cincinnati.
Noting that the "roll-out of antiretroviral treatment for HIV in sub-Saharan Africa has been accompanied by rising rates of drug resistance," Raph Hamers, a global health research fellow at the Academic Medical Centre of the University of Amsterdam, and colleagues "call for improved patient management and the integration of population-based drug resistance surveillance into national treatment programs" in this BMJ analysis.
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the lab of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole is Highly Synergistic with HCV Protease Inhibitors".
› Verified 9 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Niagara Dialysis Center get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .83 (As Expected) |
| SIR: Upper Confidence Limit | 2.26 |
| SIR: Lower Confidence Limit | .21 |
News Archive
By solving a long standing scientific mystery, the common saying "you just hit a nerve" might need to be updated to "you just hit a Merkel cell," jokes Jianguo Gu, PhD, a pain researcher at the University of Cincinnati.
Noting that the "roll-out of antiretroviral treatment for HIV in sub-Saharan Africa has been accompanied by rising rates of drug resistance," Raph Hamers, a global health research fellow at the Academic Medical Centre of the University of Amsterdam, and colleagues "call for improved patient management and the integration of population-based drug resistance surveillance into national treatment programs" in this BMJ analysis.
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the lab of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole is Highly Synergistic with HCV Protease Inhibitors".
› Verified 9 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Niagara Dialysis Center's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 43 |
| Transfusion Rate in facility | 52.4 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 152.1 |
| Transfusion Rate: Lower Confidence Limit | 20.6 |
News Archive
By solving a long standing scientific mystery, the common saying "you just hit a nerve" might need to be updated to "you just hit a Merkel cell," jokes Jianguo Gu, PhD, a pain researcher at the University of Cincinnati.
Noting that the "roll-out of antiretroviral treatment for HIV in sub-Saharan Africa has been accompanied by rising rates of drug resistance," Raph Hamers, a global health research fellow at the Academic Medical Centre of the University of Amsterdam, and colleagues "call for improved patient management and the integration of population-based drug resistance surveillance into national treatment programs" in this BMJ analysis.
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the lab of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole is Highly Synergistic with HCV Protease Inhibitors".
› Verified 9 days ago
The rate of mortality show you whether patients who were being treated regularly at Niagara Dialysis Center lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 92 |
| Mortality Rate in facility | 13.8 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 26.2 |
| Mortality Rate: Lower Confidence Limit | 6.3 |
News Archive
By solving a long standing scientific mystery, the common saying "you just hit a nerve" might need to be updated to "you just hit a Merkel cell," jokes Jianguo Gu, PhD, a pain researcher at the University of Cincinnati.
Noting that the "roll-out of antiretroviral treatment for HIV in sub-Saharan Africa has been accompanied by rising rates of drug resistance," Raph Hamers, a global health research fellow at the Academic Medical Centre of the University of Amsterdam, and colleagues "call for improved patient management and the integration of population-based drug resistance surveillance into national treatment programs" in this BMJ analysis.
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the lab of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole is Highly Synergistic with HCV Protease Inhibitors".
› Verified 9 days ago
Fresenius Kidney Care - Niagara Location: 3018 Military Road, Niagara Falls, New York, 14304 Phone: (716) 298-4195 |
Niagara Falls Kidney Care Center Location: 621 10th Street, Niagara Falls, New York, 14301 Phone: (716) 278-4639 |
Niagara Dialysis Center Location: 2932 Military Road, Niagara Falls, New York, 14304 Phone: (716) 297-4059 |
News Archive
By solving a long standing scientific mystery, the common saying "you just hit a nerve" might need to be updated to "you just hit a Merkel cell," jokes Jianguo Gu, PhD, a pain researcher at the University of Cincinnati.
Noting that the "roll-out of antiretroviral treatment for HIV in sub-Saharan Africa has been accompanied by rising rates of drug resistance," Raph Hamers, a global health research fellow at the Academic Medical Centre of the University of Amsterdam, and colleagues "call for improved patient management and the integration of population-based drug resistance surveillance into national treatment programs" in this BMJ analysis.
Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the lab of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole is Highly Synergistic with HCV Protease Inhibitors".
› Verified 9 days ago